Donna L. LaVoie discusses four key industry areas that will experience downstream pressures in the wake of the COVID-19 crisis.
Donna L. LaVoie
Advertisement
Donna L. LaVoie is President & CEO of LaVoieHealthScience.
Articles by Donna L. LaVoie
Advertisement
Latest Updated Articles
COVID-19: Four Challenges for Issue Management TeamsPublished: April 17th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
2
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
3
Is FDA Streamlining Regulations in the Biosimilar Space?
4
Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists
5
